Phase II Study of MM 398 in Pancreatic Cancer published
Results from a Phase II study of PEP02, also known as MM 398 (nanoliposomal irinotecan), from Merrimack Pharmaceuticals, as second-line treatment for Pancreatic Cancer, show the drug met its primary endpoints and details have been published in the British Journal of Cancer. A total of 40 patients were enrolled. The most common severe adverse events included neutropenia, abdominal pain, asthenia, and diarrhoea. Three patients achieved an objective response, with an additional 17 (42.5%) demonstrating stable disease for a minimum of two cycles. Ten (31.3%) of 32 patients with an elevated baseline CA19-9 had more than 50% biomarker decline.
The study met its primary end point with an OS3-month of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively. See: �A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02 MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer� A H Ko et al. British Journal of Cancer, August 2013: 109 (4): p920-925 doi:10.1038/bjc.2013.408
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins